Literature DB >> 15828286

[Promoter hypermethylation of tumor-associated genes in head and neck cancer].

Kenji Okami1, Akihiro Sakai, Junichi Onuki, Takahide Hamano, Masahiro Iida, Masahiro Takahashi.   

Abstract

An important pathway of gene transcriptional inactivation is hypermethylation at the CpG islands of promoter regions. Some tumor suppressor genes have been reported to harbor promoter hypermethylation in head and neck cancer. We studied DNA hypermethylation of 4 genes in 42 cases of primary head and neck cancer. We applied methylation specific PCR for p16, RAR-beta, RASSF1A, and Fhit genes. Hypermethylation was detected at p16 in 43%, at RAR-beta in 40%, at RASSF1A in 12%, and at Fhit in none of the cases. Hypermethylation of at least one gene was detected in 26 (62%) of the 42 cases. No significant correlation was seen between methylation status and clinicopathological findings or prognosis. Hypermethylation of several tumor-associated genes plays an important role in tumorigenesis of head and neck cancer. We discuss clinical implications and their application.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15828286     DOI: 10.3950/jibiinkoka.108.207

Source DB:  PubMed          Journal:  Nihon Jibiinkoka Gakkai Kaiho        ISSN: 0030-6622


  3 in total

1.  PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population.

Authors:  P S Sushma; Kaiser Jamil; P Uday Kumar; U Satyanarayana; M Ramakrishna; B Triveni
Journal:  Tumour Biol       Date:  2015-12-19

Review 2.  Histone modifications: Targeting head and neck cancer stem cells.

Authors:  John M Le; Cristiane H Squarize; Rogerio M Castilho
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

3.  Role of DNA methylation in head and neck cancer.

Authors:  Semra Demokan; Nejat Dalay
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.